Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study

• Main Authors: Juan Antonio García-Carmona (Author), Alba García-Pérez (Author), Guillermo Isidro García (Author), Luis Alberto Forcen-Muñoz (Author), Santiago Ovejero García (Author), Rocío Sáez Povedano (Author), Ana Luisa González-Galdámez (Author), Laura Mata Iturralde (Author), Fernando Hernández-Sánchez (Author), Mariluz Ramirez Bonilla (Author), Paloma Fuentes-Pérez (Author), Claudia Ovejas-Catalán (Author), Paula Suárez-Pinilla (Author), Francisco Valdivia-Muñoz (Author), Blanca Fernández Abascal (Author), Miguel Omaña Colmenares (Author), Ángela de Lourdes Martín-Pérez (Author), María Pilar Campos-Navarro (Author), Enrique Baca-García (Author), Sergio Benavente-López (Author), Alberto Raya Platero (Author), Miguel Barberán Navalón (Author), Sergio Sánchez-Alonso (Author), Javier Vázquez-Bourgon (Author), Sofia Pappa (Author)
• Format: Book
• Published: SAGE Publishing, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Paliperidone palmitate 6-monthly (PP6M) is the first long-acting antipsychotic injectable (LAI) to allow for only two medication administrations per year, though there is presently limited insight into its effectiveness and potential added value in real clinical practice conditions. Obje...